Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025)
Pulmonx (LUNG) posted quarterly Cash from Financing Activities of $181000.0 for Q3 2025, down 60.57% year-over-year from $459000.0 in Q3 2024, and up 370.15% quarter-over-quarter from -$67000.0 in Q2 2025.
Pulmonx (LUNG) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Pulmonx (LUNG) has reported Cash from Financing Activities for 7 consecutive years, with $181000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Financing Activities fell 60.57% year-over-year to $181000.0; the TTM figure through Sep 2025 stood at $840000.0 (down 36.27% YoY), while the FY2024 annual figure was $1.4 million, down 93.63% from the prior year.
- Cash from Financing Activities grew to $181000.0 in Q3 2025 per LUNG's latest filing, from -$67000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $20.7 million in Q1 2023 and bottomed at -$67000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $1.6 million across 5 years, with a median of $181000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities jumped 10015.38% — and 2025, when it slumped 204.55%.
- Pulmonx's Cash from Financing Activities stood at $150000.0 in 2021, then tumbled by 55.33% to $67000.0 in 2022, then slumped by 74.63% to $17000.0 in 2023, then jumped by 264.71% to $62000.0 in 2024, then soared by 191.94% to $181000.0 in 2025.
- Business Quant data shows LUNG's Cash from Financing Activities at $181000.0 in Q3 2025, -$67000.0 in Q2 2025, and $664000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Pulmonx | 93.95 Mn | 24.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | -67,000.00 |
| Jun 30, 2025 | -67,000.00 |
| Mar 31, 2025 | 664,000.00 |
| Mar 31, 2025 | 664,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Dec 31, 2024 | 62,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Jun 30, 2024 | -22,000.00 |
| Jun 30, 2024 | -22,000.00 |
| Mar 31, 2024 | 864,000.00 |
| Mar 31, 2024 | 864,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 571,000.00 |
| Sep 30, 2023 | 571,000.00 |
| Jun 30, 2023 | 92,000.00 |
| Jun 30, 2023 | 92,000.00 |